CL2012000351A1 - Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos. - Google Patents

Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos.

Info

Publication number
CL2012000351A1
CL2012000351A1 CL2012000351A CL2012000351A CL2012000351A1 CL 2012000351 A1 CL2012000351 A1 CL 2012000351A1 CL 2012000351 A CL2012000351 A CL 2012000351A CL 2012000351 A CL2012000351 A CL 2012000351A CL 2012000351 A1 CL2012000351 A1 CL 2012000351A1
Authority
CL
Chile
Prior art keywords
compounds
procedure
preparation
cholesterol
pharmaceutical composition
Prior art date
Application number
CL2012000351A
Other languages
English (en)
Inventor
Ying Chen
Hua Bai
Xuyang Zhao
Xiaojie Xu
Xiaoyu Liu
Yuncai Zhang
Xiaohe Zheng
Maojian Gu
Qifeng Zhu
Yong Zhang
Hairong Lou
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of CL2012000351A1 publication Critical patent/CL2012000351A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DERIVADOS DE AZETLDLN-2-ONA DE FÓRMULA 1   DONDE QUE RL, R2, R3, R4, RS Y R6 SON COMO SE DEFINEN EN PLIEGO DE REIVINDICACIONES; PROCEDIMIENTO DE PREPARACIÓN DE LOS MISMOS;<br /> COMPOSICIÓN FARMACÉUTICA; USO DE LOS COMPUESTOS EN LA REDUCCIÓN DE LOS NIVELES DE COLESTEROL TOTAL (CT) Y COLESTEROL DE LLPOPROTEÍNAS DE<br /> BAJA DENSIDAD (LDL-C) EN PLASMA; COMPUESTOS INTERMEDIOS IV Y V Y PROCEDIMIENTO DE PREPARACIÓN DEL COMPUESTO INTERMEDIARIO V.
CL2012000351A 2009-08-11 2012-02-10 Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos. CL2012000351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101628888A CN101993403B (zh) 2009-08-11 2009-08-11 氮杂环丁酮类化合物及医药应用

Publications (1)

Publication Number Publication Date
CL2012000351A1 true CL2012000351A1 (es) 2012-08-10

Family

ID=43585888

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000351A CL2012000351A1 (es) 2009-08-11 2012-02-10 Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos.

Country Status (18)

Country Link
US (1) US8623855B2 (es)
EP (1) EP2465847B1 (es)
JP (1) JP5706896B2 (es)
KR (1) KR101394993B1 (es)
CN (2) CN101993403B (es)
CA (1) CA2770793C (es)
CL (1) CL2012000351A1 (es)
EA (1) EA021484B1 (es)
IL (1) IL218045A (es)
IN (1) IN2012DN01132A (es)
MX (1) MX2012001829A (es)
MY (1) MY157237A (es)
NZ (1) NZ598050A (es)
PE (1) PE20121086A1 (es)
SG (1) SG178313A1 (es)
UA (1) UA105053C2 (es)
WO (1) WO2011017907A1 (es)
ZA (1) ZA201201676B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
EP2905276A4 (en) * 2012-09-05 2016-03-09 Zhejiang Hisun Pharm Co Ltd CRYSTALLINE FORMS OF AZETIDINONE COMPOUNDS AND MANUFACTURING METHOD
CN104780918B (zh) * 2013-03-01 2017-03-08 浙江海正药业股份有限公司 用于预防和/或治疗丙型肝炎的氮杂环丁酮化合物及其组合物
CN105294426B (zh) 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN117085011A (zh) * 2017-11-23 2023-11-21 浙江海正药业股份有限公司 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物
WO2019101150A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布片剂及其制备方法
EP4357333A4 (en) * 2021-06-17 2025-08-27 Zhejiang Hisun Pharm Co Ltd HYSTEETIMIBE INTERMEDIATE AND PROCESS FOR ITS PREPARATION

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223059B (es) 1991-07-23 1994-05-01 Schering Corp
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0766667A1 (en) 1994-06-20 1997-04-09 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE60106489T2 (de) 2000-12-20 2005-10-13 Schering Corp. Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
HUP0401081A3 (en) * 2000-12-21 2010-06-28 Sanofi Aventis Deutschland Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HRP20030501A2 (en) 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
CN101134739A (zh) * 2006-09-01 2008-03-05 长春吉大天元化学技术股份有限公司 新的β-内酰胺类化合物及其制备方法及其药物用途
WO2008057948A2 (en) * 2006-11-01 2008-05-15 Ironwood Pharmaceuticals, Inc. Processes for production of diphenylylazetidin-2-ones and related compounds
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds
CN101423511A (zh) * 2007-11-05 2009-05-06 中山奕安泰医药科技有限公司 依泽替米贝中间体及依泽替米贝的合成方法
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用

Also Published As

Publication number Publication date
IN2012DN01132A (es) 2015-04-10
AU2010282097A1 (en) 2012-04-05
MX2012001829A (es) 2012-07-23
IL218045A0 (en) 2012-04-30
EA021484B1 (ru) 2015-06-30
IL218045A (en) 2017-05-29
NZ598050A (en) 2013-03-28
CN102448932A (zh) 2012-05-09
CN102448932B (zh) 2014-08-13
US20120208994A1 (en) 2012-08-16
ZA201201676B (en) 2012-11-28
CN101993403B (zh) 2012-07-11
PE20121086A1 (es) 2012-08-17
MY157237A (en) 2016-05-13
CA2770793A1 (en) 2011-02-17
KR20120047969A (ko) 2012-05-14
CN101993403A (zh) 2011-03-30
KR101394993B1 (ko) 2014-05-15
SG178313A1 (en) 2012-03-29
UA105053C2 (uk) 2014-04-10
WO2011017907A1 (zh) 2011-02-17
JP5706896B2 (ja) 2015-04-22
JP2013501734A (ja) 2013-01-17
EP2465847A1 (en) 2012-06-20
EA201270248A1 (ru) 2012-07-30
US8623855B2 (en) 2014-01-07
EP2465847A4 (en) 2013-04-17
EP2465847B1 (en) 2016-10-12
CA2770793C (en) 2017-06-13

Similar Documents

Publication Publication Date Title
PA8827001A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
PH12013500942A1 (en) Triazolopyridine compounds
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
ECSP10010291A (es) Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno
ECSP10010722A (es) Compuestos orgánicos
MX336741B (es) Composiciones farmaceuticas de moduladores de c-met.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2008003158A1 (es) Compuestos derivados de diariltiohidantoina con actividad antagonista fuerte y con actividad agonista minima sobre el receptor de androgeno (ar); procedimiento de preparacion; composicion farmaceutica que los comprende; uso en el tratamiento de un desorden proliferativo tal como cancer de prostata.
BR112012029647A2 (pt) novos derivados de pirimidinas
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
MX2015016058A (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
UY32623A (es) Derivados bicíclicos para afecciones asociadas al receptor de andrógenos
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
CL2010001432A1 (es) Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas.